Feedstock Additive Co. Gets Massive Order for Brazil Market
Source: Streetwise Reports  (8/11/22)
The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health. More >

Testing Confirms Drug Candidate Differs From Peers
Source: Dr. Douglas Loe  (8/10/22)
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report. More >

Demand for Co.’s Antibiotic Free Animal Feed Is Raising
Source: Clive Maund  (8/10/22)
With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company. More >

Pharma Co. Achieves Record Sales of LEMS Drug in Q2
  (8/10/22)
Shares of Catalyst Pharmaceuticals Inc. traded 24% higher to a new 52-week high after the company reported that in Q2/22 net product revenues from sales of its FIRDAPSE® increased 57.7% YoY to $53.0 million. FIRDAPSE® has been approved by both the U.S. FDA and Health Canada as a treatment for adult patients with Lambert-Eaton myasthenic syndrome, a rare autoimmune disease in which a person's immune system attacks its body's own tissues at the neuromuscular junction. More >

Biotech Co. Awakes To Good News
Source: Clive Maund  (8/6/22)
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development. More >

Biopharma Co. Planning BLA for DMD Drug
Source: Yun Zhong, Ph.D.  (8/5/22)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares. More >

Environmental Tech Co. Builds up to a Major Bull Market
Source: Clive Maund  (8/4/22)
After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market. More >

ChemoCentryx Shares Double on $4B Cash Bid from Amgen
Source: Streetwise Reports  (8/4/22)
Shares of ChemoCentryx Inc. traded 110% higher after the company reported it agreed to be acquired by Amgen Inc. for $52.00 per share in an all-cash deal valued at $4 billion. With the purchase, Amgen aims to cement its leadership position in inflammation and nephrology with the addition of ChemoCentryx's TAVNEOS® (avacopan) which the U.S. FDA approved late last year to treat ANCA-associated vasculitis, a serious autoimmune disease. More >

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study
Source: Clive Maund  (8/2/22)
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil. More >

Tech Co. ‘Right at the Point of Breakout'
Source: Clive Maund  (8/2/22)
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news. More >

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment
Source: Andre Uddin  (8/1/22)
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company. More >

Drug Candidate Repairs Motor/Sensory Function in Stroke
Source: Streetwise Reports  (7/29/22)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event. More >

Additional Study Review Reveals Patients Coughed Much Less
Source: Streetwise Reports  (7/28/22)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought. More >

Biotech Co. Granted New Patent for Breast Cancer Vaccine
  (7/27/22)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa. More >

Biopharma Co. Signs Exclusive License Deal for Ricin Antigen
Source: Streetwise Reports  (7/27/22)
Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning. More >

Cancer Co.'s Price Target Adjusted After Reverse Stock Split
  (7/25/22)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share. More >

Radiotherapy Co. On-Track With Two Clinical Trials
  (7/24/22)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22. More >

Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports  (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >

Biotech Co.'s Phase 3 Trial First to Get Grant
Source: Streetwise Reports  (7/20/22)
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price. More >

Drug Repurposing Co. Provides Opportunity for High Rewards
  (7/20/22)
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company. More >

Trial Results Show New Drug Improves Dry Eye Symptoms
Source: Matthew Caufield   (7/19/22)
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Looks to Expand New Drug Label Down the Road
  (7/18/22)
ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report. More >

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’
Source: Patrick Trucchio  (7/15/22)
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD. More >

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial
Source: Streetwise Reports  (7/15/22)
Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial. More >

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial
Source: Streetwise Reports  (7/14/22)
Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%. More >